Drugs / DermaVir
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00712530 | Jan 2005 → Jun 2006 | HIV infectious disease | Genetic Immunity | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00614640 | ? → Nov 2013 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00711230 | Apr 2008 → Dec 2011 | HIV infectious disease | Genetic Immunity | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DermaVir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00711230 ↗ |
| Modality | Vaccine | “The therapeutic DNA vaccine, DermaVir, represents an immunization strategy” NCT00614640 ↗ |
| Route | Topical | “Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours” NCT00614640 ↗ |